There is considerable interest in developing new multipurpose prevention technologies to address women's reproductive health needs. This study describes an innovative barrier contraceptive device--based on the SILCS diaphragm--that also provides long-term controlled release of the lead candidate anti-HIV microbicide dapivirine. Diaphragm devices comprising various dapivirine-loaded polymer spring cores overmolded with a nonmedicated silicone elastomer sheath were fabricated by injection molding processes. In vitro release testing, thermal analysis and mechanical characterization were performed on the devices. A diaphragm device containing a polyoxymethylene spring core loaded with 10% w/w dapivirine provided continuous and controlled release of dapivirine over a 6-month period, with a mean in vitro daily release rate of 174 mcg/day. The mechanical properties of the new diaphragm were closely matched to the SILCS diaphragm. The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission. In discontinuous clinical use, release of dapivirine may be readily extended over 1 or more years.
There is considerable interest in developing new multipurpose prevention technologies to address women 's reproductive health needs . This study describes an innovative barrier contraceptive device -- based on the SILCS diaphragm -- that also provides long - term controlled release of the lead candidate anti - HIV microbicide dapivirine . Diaphragm devices comprising various dapivirine - loaded polymer spring cores overmolded with a nonmedicated silicone elastomer sheath were fabricated by injection molding processes . In vitro release testing , thermal analysis and mechanical characterization were performed on the devices . A diaphragm device containing a polyoxymethylene spring core loaded with 10 % w / w dapivirine provided continuous and controlled release of dapivirine over a 6-month period , with a mean in vitro daily release rate of 174 mcg / day . The mechanical properties of the new diaphragm were closely matched to the SILCS diaphragm . The study demonstrates proof of concept for a dapivirine - releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission . In discontinuous clinical use , release of dapivirine may be readily extended over 1 or more years .
Which infection can be prevented with Dapivirine?
Which infection can be prevented with Dapivirine ?
HIV
HIV